Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

SNSE

Sensei Biotherapeutics Inc

Last Close
Apr 16 • 03:48PM ET
1.01
Dollar change
+0.00
Percentage change
0.50 		%
Held by: VTI VXF IWC Scroll to Statements
Index- P/E- EPS (ttm)-1.21 Insider Own35.02% Shs Outstand25.03M Perf Week-8.18%
Market Cap25.32M Forward P/E- EPS next Y-1.04 Insider Trans0.00% Shs Float16.29M Perf Month0.00%
Income-34.10M PEG- EPS next Q-0.27 Inst Own11.02% Short Float0.96% Perf Quarter38.36%
Sales0.00M P/S- EPS this Y19.37% Inst Trans-0.13% Short Ratio2.22 Perf Half Y36.49%
Book/sh2.59 P/B0.39 EPS next Y-5.23% ROA-35.38% Short Interest0.16M Perf Year-32.67%
Cash/sh2.62 P/C0.39 EPS next 5Y- ROE-40.52% 52W Range0.51 - 1.93 Perf YTD45.95%
Dividend Est.- P/FCF- EPS past 5Y-16.26% ROI-49.66% 52W High-47.56% Beta0.15
Dividend TTM- Quick Ratio11.92 Sales past 5Y0.00% Gross Margin- 52W Low98.04% ATR (14)0.10
Dividend Ex-Date- Current Ratio11.92 EPS Y/Y TTM23.36% Oper. Margin0.00% RSI (14)49.47 Volatility9.96% 9.62%
Employees27 Debt/Eq0.10 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price4.67
Option/ShortNo / Yes LT Debt/Eq0.06 EPS Q/Q25.56% Payout- Rel Volume0.82 Prev Close1.00
Sales Surprise- EPS Surprise2.47% Sales Q/Q- EarningsFeb 28 BMO Avg Volume70.46K Price1.01
SMA20-4.65% SMA507.86% SMA20014.06% Trades Volume56,912 Change0.50%
Date Action Analyst Rating Change Price Target Change
Jul-01-21Downgrade Berenberg Buy → Hold $12
Jun-29-21Downgrade Oppenheimer Outperform → Perform $30 → $14
Mar-01-21Initiated Piper Sandler Overweight $25
Mar-01-21Initiated Oppenheimer Outperform $36
Mar-01-21Initiated Citigroup Buy $30
Mar-01-21Initiated Berenberg Buy $27
Apr-09-24 07:30AM
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
(GlobeNewswire) +6.28%
Apr-04-24 04:05PM
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
(GlobeNewswire)
Mar-22-24 07:30AM
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
(GlobeNewswire) +11.43%
Mar-06-24 07:30AM
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
(GlobeNewswire)
Feb-28-24 07:30AM
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
(GlobeNewswire) +9.09%
07:30AM Loading…
Feb-07-24 07:30AM
Sensei Biotherapeutics to Present at Upcoming Conferences
(GlobeNewswire) +6.12%
Jan-04-24 07:30AM
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
(GlobeNewswire)
Nov-07-23 08:09AM
Sensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Results
(GuruFocus.com) -7.15%
07:30AM
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
(GlobeNewswire)
Nov-03-23 04:05PM
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
(GlobeNewswire) -13.75%
Nov-01-23 07:30AM
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
(GlobeNewswire) +15.33%
Oct-25-23 09:05AM
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
(GlobeNewswire)
Oct-23-23 07:30AM
Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
(GlobeNewswire)
Sep-27-23 07:30AM
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron s Libtayo
(GlobeNewswire) -10.17%
Sep-21-23 07:30AM
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
(GlobeNewswire)
07:30AM Loading…
Sep-13-23 07:30AM
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
(GlobeNewswire)
Aug-30-23 07:30AM
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-19-23 10:44AM
Billionaire Stan Druckenmillers Small-Cap Stock Picks
(Insider Monkey)
Aug-03-23 07:30AM
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
(GlobeNewswire)
Aug-02-23 07:30AM
Sensei Biotherapeutics to Participate in Canaccord Genuitys 43rd Annual Growth Conference
(GlobeNewswire)
Jun-13-23 07:30AM
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, A New Vista for Cancer Care: Exploring SNS-101s Potential as a Transformative Treatment Option for Patients with Solid Tumors
(GlobeNewswire)
Jun-01-23 07:30AM
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
(GlobeNewswire)
May-31-23 07:30AM
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
(GlobeNewswire)
May-09-23 07:30AM
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
(GlobeNewswire)
Apr-20-23 07:30AM
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
(GlobeNewswire)
Apr-18-23 04:05PM
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
(GlobeNewswire)
Apr-13-23 07:30AM
Sensei Biotherapeutics to Participate in Canaccord Genuitys Horizons in Oncology Virtual Conference
(GlobeNewswire)
Mar-30-23 07:30AM
Sensei Biotherapeutics to Participate in Cantor Fitzgeralds Future of Oncology Virtual Symposium
(GlobeNewswire) +6.11%
Mar-28-23 07:30AM
Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights
(GlobeNewswire)
Mar-23-23 11:56AM
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
(Simply Wall St.)
07:30AM Loading…
Mar-21-23 07:30AM
Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
(GlobeNewswire)
Mar-14-23 04:35PM
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023
(GlobeNewswire) +9.92%
Mar-07-23 05:15PM
Sensei Biotherapeutics Adopts Stockholder Rights Agreement
(GlobeNewswire) +6.49%
Mar-06-23 07:30AM
Sensei Biotherapeutics to Participate in Oppenheimers 33rd Annual Healthcare Conference
(GlobeNewswire)
Feb-21-23 07:30AM
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
(GlobeNewswire) -7.14%
Feb-16-23 07:30AM
Sensei Biotherapeutics to Participate in Citis 2023 Virtual Oncology Leadership Summit
(GlobeNewswire)
Feb-14-23 07:30AM
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
(GlobeNewswire)
Feb-06-23 07:30AM
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
(GlobeNewswire)
Jan-05-23 07:30AM
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors
(GlobeNewswire)
Dec-08-22 01:10PM
Immunotherapy startup shutters Boston research site, lays off 17
(American City Business Journals)
10:40AM
Sensei Biotherapeutics Slashes Workforce, Closes R&D Site
(Benzinga)
07:30AM
Sensei Biotherapeutics Provides Update on Strategic Priorities
(GlobeNewswire)
Nov-22-22 07:30AM
Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
(GlobeNewswire)
Nov-21-22 07:30AM
Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody
(GlobeNewswire)
06:00AM
Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate
(GlobeNewswire)
Nov-10-22 09:00AM
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
(GlobeNewswire) +9.49%
Nov-08-22 07:30AM
Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire)
Nov-07-22 07:30AM
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint
(GlobeNewswire)
Nov-02-22 07:30AM
Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
(GlobeNewswire)
Oct-14-22 10:22AM
We're Keeping An Eye On Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Rate
(Simply Wall St.)
Oct-05-22 08:05AM
Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
(GlobeNewswire)
Sep-30-22 04:05PM
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
(GlobeNewswire)
Sep-21-22 04:05PM
Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
(GlobeNewswire) -5.32%
Aug-31-22 07:30AM
Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody
(GlobeNewswire)
Aug-23-22 07:30AM
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-11-22 07:02AM
One Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insider upped their stake by 13% in the previous year
(Simply Wall St.)
Aug-09-22 07:30AM
Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire) -5.37%
Jun-01-22 07:30AM
Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer
(GlobeNewswire)
May-25-22 07:30AM
Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
(GlobeNewswire) -6.32%
May-10-22 07:30AM
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
(GlobeNewswire) +9.80%
May-07-22 09:40AM
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
(Simply Wall St.)
Apr-21-22 09:09AM
9 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller
(Insider Monkey)
Mar-10-22 07:30AM
Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
(GlobeNewswire) -7.62%
Mar-09-22 04:05PM
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
(GlobeNewswire) +6.49%
Mar-03-22 07:30AM
Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference
(GlobeNewswire) -5.36%
Feb-11-22 07:30AM
Sensei Biotherapeutics to Participate in Citis 2022 Virtual Immuno-Oncology Summit
(GlobeNewswire)
Jan-17-22 11:22AM
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insiders placed bullish bets worth US$1.0m in the last 12 months
(Simply Wall St.)
Jan-06-22 08:00AM
Sensei Biotherapeutics Announces Executive Promotions
(GlobeNewswire)
Dec-16-21 09:01AM
Sensei Biotherapeutics Named a Winner of Comparablys Best CEO Award
(GlobeNewswire)
Dec-13-21 04:01PM
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
(GlobeNewswire)
Nov-19-21 04:02PM
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
(GlobeNewswire) -5.69%
Nov-17-21 10:37AM
What Percentage Of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Do Insiders Own?
(Simply Wall St.) -5.10%
Nov-12-21 07:02AM
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
(GlobeNewswire) +11.09%
Nov-09-21 08:54AM
Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
(GlobeNewswire)
Nov-03-21 09:01AM
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
(GlobeNewswire)
Oct-01-21 08:05AM
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
(GlobeNewswire)
Aug-17-21 01:56PM
Here's Why We're Not Too Worried About Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
(Simply Wall St.)
Aug-09-21 12:00PM
Sensei Biotherapeutics, Inc. (SNSE) Upgraded to Buy: Here's Why
(Zacks)
Aug-04-21 07:45AM
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
(GlobeNewswire)
Aug-02-21 08:01AM
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
(GlobeNewswire)
Jun-29-21 01:49PM
These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
(Motley Fool) -15.97%
Jun-28-21 04:05PM
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
(GlobeNewswire)
May-19-21 05:03PM
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
(GlobeNewswire) +5.42%
May-12-21 07:41AM
Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
(GlobeNewswire)
May-05-21 08:05AM
Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board
(GlobeNewswire)
May-04-21 07:18AM
What Percentage Of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Do Insiders Own?
(Simply Wall St.) -8.48%
Apr-05-21 08:00AM
Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors
(GlobeNewswire)
Mar-25-21 08:00AM
Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update
(GlobeNewswire)
Mar-22-21 08:00AM
Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index
(GlobeNewswire)
Mar-09-21 08:30AM
Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference
(GlobeNewswire) +7.74%
Mar-05-21 03:30PM
Oppenheimer: 2 Stocks That Could Climb Over 100%
(TipRanks)
Feb-10-21 04:55PM
Sensei Biotherapeutics Announces Closing of Initial Public Offering
(GlobeNewswire) -7.32%
Feb-09-21 11:08AM
Cambrian Biopharma announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy
(PR Newswire) -9.89%
Feb-05-21 05:26PM
The Wave of Biotech IPOs Continues. Here Are 7 Stocks That Hit the Market
(Barrons.com) +18.99%
Feb-04-21 05:56PM
A Busy Day for Biotech IPOs
(Barrons.com)
Feb-03-21 08:44PM
Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering
(GlobeNewswire)
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Celebi JohnPresident and CEOSep 11 '23Buy0.85500425111,311Sep 13 08:43 AM
Apeiron Investment Group Ltd.10% OwnerJun 01 '23Sale1.583,441,6615,437,8240Jun 02 05:03 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.